10-K: Establishment Labs Reports Strong 2025 Revenue Growth

Establishment Labs Holdings Inc. reported a 27.2% revenue increase to $211.1 million in 2025, driven by strong U.S. market entry and improved EMEA/Latin America demand, despite continued net losses.

Summary

• Revenue increased by 27.2% to $211.1 million for the year ended December 31, 2025, compared to $166.0 million in 2024.
• Net loss decreased to $51.1 million in 2025 from $84.6 million in 2024.
• Gross margin improved to 69.3% in 2025, up from 66.0% in 2024, primarily due to higher selling prices in the United States.
• U.S. sales of Motiva Implants reached $45.6 million in 2025, with over 1,500 accounts secured.
• The company launched Preserv, a minimally invasive breast tissue-preserving technology, in Brazil and an early experience group in the U.S. in February 2025, with a full U.S. launch expected in 2026.
• Positive 3-year results from the Mia Femtech clinical study were published, showing a 1% reoperation rate and no reports of capsular contracture, implant rupture, or sensation loss.
• Secured a $25 million Tranche D Term Loan in September 2025 and a $10 million Inventory Funding Agreement to finance silicone raw material purchases.
• The accumulated deficit as of December 31, 2025, was $495.8 million, with a cash balance of $75.6 million.
• Research and development expenses increased slightly to $20.2 million in 2025 from $19.7 million in 2024.
• Sales, general and administrative expenses increased by 18.1% to $165.1 million in 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, demonstrating strong revenue growth and improved gross margins, particularly with successful U.S. market penetration and positive clinical data. However, continued net losses and reliance on a single supplier for critical raw materials temper the overall sentiment.

Positives

• Achieved significant revenue growth of 27.2% year-over-year, reaching $211.1 million in 2025.
• Reduced net loss by 39.6% from $84.6 million in 2024 to $51.1 million in 2025.
• Improved gross margin to 69.3% in 2025, driven by higher selling prices in the U.S. market.
• Successfully entered the U.S. market for Motiva Implants, generating $45.6 million in sales and securing over 1,500 accounts in 2025.
• Published positive 3-year clinical study results for Mia Femtech, demonstrating very low complication rates (0% for capsular contracture, rupture, infection, seroma, hematoma, sensation loss) and high patient/surgeon satisfaction.
• Launched Preserv, a new minimally invasive breast tissue-preserving technology, in Brazil and an early experience group in the U.S.
• Expanded manufacturing capacity by approximately 730,000 units per year with the new LEED Platinum and EDGE Advanced certified Sulym Innovation Campus.
• Received FDA authorization for Costa Rican facilities to manufacture all Motiva USA PMA-approved products, enhancing U.S.-bound production capacity.
• Released a $9.4 million valuation allowance on U.S. deferred tax assets due to improved financial outlook for the U.S. subsidiary.
• Management concluded that internal control over financial reporting was effective as of December 31, 2025, addressing previous material weaknesses.

Negatives

• Continued to incur net losses, with an accumulated deficit of $495.8 million as of December 31, 2025.
• Cash and cash equivalents decreased from $90.3 million in 2024 to $75.6 million in 2025.
• Overall operating expenses increased, with SG&A up 18.1% to $165.1 million and R&D up 2.5% to $20.2 million.
• Asia-Pacific revenue decreased by 28.6% in 2025, primarily due to distributor inventory sell-through and lower consumer demand in China.
• Reliance on a single-source, third-party supplier (Avantor) for medical-grade silicone, with Avantor indicating it does not intend to automatically renew the supply agreement after December 31, 2026.
• Increased minimum liquidity requirement from $25 million to $30 million under the Credit Agreement.
• Exposure to economic and political instability in emerging markets and adverse fluctuations in currency rates.
• Potential for glucagon-like peptide-1 (GLP-1) drugs to reduce discretionary consumer spending on elective aesthetic procedures.

Risks

• Unfavorable global economic and political conditions, including slower growth, recession, inflation, decreased consumer spending, or trade wars, could adversely affect the business.
• The company has incurred losses to date, and its ability to achieve and maintain profitability depends on the commercial success of Motiva Implants.
• Insufficient available cash resources and anticipated cash flow from operations may necessitate seeking additional equity or debt financing, potentially leading to dilution or restrictive covenants.
• A limited operating history in the United States may lead to difficulties in commercialization within competitive and rapidly evolving markets.
• Failure to maintain brand reputation and ongoing customer demand for products and services, or a significant reduction in sentiment, could affect results of operations.
• Inability to compete effectively against competitors, many of whom have greater resources, could negatively affect revenues and results of operations.
• Any disruption at existing manufacturing facilities in Costa Rica could adversely affect business and operating results.
• Failure to maintain and develop a direct sales force, or ineffective sales personnel, could negatively impact revenues and financial outcomes.
• Inability to educate clinicians on the safe, effective, and appropriate use of products and designed surgeries may lead to unsatisfactory patient outcomes, negative publicity, and increased product liability claims.
• Success depends on the ability to enhance existing products and develop or commercialize new ones, which requires significant expenses and may not receive regulatory approval or market acceptance.
• Delays or failure to obtain necessary regulatory clearances or approvals would adversely affect the ability to grow the business.
• Compliance with ongoing regulatory obligations and continued regulatory review may result in significant additional expense and subject the company to penalties.
• Reliance on a single-source, third-party supplier (Avantor) for medical-grade long-term implantable silicone, with risks of price increases or supply interruptions, and Avantor's non-renewal of the supply agreement.
• Significant exposure to economic and political situations in emerging market countries, which could materially impact financial results.
• Pandemics, epidemics, or other public health crises may adversely affect business and financial results in the future.
• Adverse developments affecting the financial services industry, such as bank failures or liquidity issues, could adversely affect liquidity and financial performance.
• Fluctuations in currency rates could adversely affect results of operations.
• Negative publicity concerning products or competitors' products, including due to product defects, recalls, litigation, or long-term safety impacts (e.g., BIA-ALCL, SCC), could harm reputation and reduce demand.
• The medical device industry is characterized by patent litigation, and the company could become subject to costly litigation to protect or enforce intellectual property rights.
• Inability to protect the confidentiality of trade secrets could materially adversely affect the value of technology.
• Information systems, or those used by third parties, may fail, be impacted by cybersecurity incidents, or suffer other forms of attack or damage.
• The use of artificial intelligence technology by employees or business partners could result in misuse or loss of proprietary information, violation of laws, or damage to reputation.
• Failure to adequately protect personal information in compliance with evolving legal requirements could harm the business.
• The regulatory approval process is expensive, time-consuming, and uncertain, potentially delaying or preventing commercialization.
• Modifications to marketed products may require new regulatory clearances or approvals, or necessitate product recalls.
• Products may be subject to product recalls that could harm reputation, business, and financial results.
• Relationships with customers, patients, and third-party payors are subject to anti-kickback, fraud and abuse, and other healthcare laws and regulations.
• Healthcare reform measures could hinder or prevent planned products' commercial success.
• Tax authorities may disagree with tax positions and conclusions, resulting in unanticipated costs, taxes, or non-realization of expected benefits.
• Discontinuation of preferential tax treatments (e.g., Costa Rica tax holiday) or other unfavorable changes in tax law could result in additional compliance obligations and costs.
• The company's share price may be volatile, and purchasers of securities could incur substantial losses.
• Identified a material weakness in internal control over financial reporting as of December 31, 2023, and 2022, which could recur and affect reporting obligations.
• Rights of shareholders under British Virgin Islands law differ from those under U.S. law, potentially offering fewer protections.
• Provisions in the amended and restated memorandum and articles of association and British Virgin Islands law could make an acquisition more difficult and prevent attempts to replace management.

Future Outlook

The company expects overall operating expenses to increase in 2026 compared to 2025 due to continued investment in commercial and operational activities following FDA approval. A full U.S. launch of Preserv is anticipated in 2026. The company does not expect to achieve profitability in 2026 and will continue to incur significant research and development expenses related to clinical trials.

Management Comments

• "Management, in collaboration with our distribution partner, is dedicated to establishing Motiva as the leading implant in China, mirroring its success in other Asian markets."
• "We expect overall operating expenses to increase as compared to 2025, although we remain focused on managing operating expenses."
• "We believe that our available cash and cash from operations will be sufficient to satisfy our liquidity requirements for at least the next 12 months."

Industry Context

StockSavvy.ai notes that the breast augmentation market remains a leading aesthetic surgical procedure globally, with approximately 1.7 million procedures performed worldwide in 2024. The global breast reconstruction market is also projected for robust growth, with a CAGR of 6.7% from 2025 to 2030, expected to exceed $3.15 billion by 2030. However, the industry faces ongoing challenges from limited innovation since the 1990s and persistent safety concerns, such as Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) and Squamous Cell Carcinoma (SCC), which have led to regulatory actions and recalls of competitors' textured implants. The emergence and growing adoption of GLP-1 drugs for obesity and metabolic conditions could also introduce a new competitive dynamic by potentially reducing discretionary consumer spending on elective aesthetic procedures.

Comparison to Industry Standards

• Motiva Implants' 5-year U.S. IDE study results demonstrate significantly lower complication rates compared to published 10-year CORE study data from major competitors (Sientra, Allergan, Mentor). For rupture, Motiva reported 0.6% versus Sientra's 8.5%, Allergan's 9.3%, and Mentor's 24.2%.
• For capsular contracture (Baker Grade III/IV), Motiva reported 0.5% compared to Sientra's 12.9%, Allergan's 18.9%, and Mentor's 12.1%.
• Reoperation rates for Motiva were 8.8% versus Sientra's 24.0%, Allergan's 36.1%, and Mentor's 25.5%.
• The Mia Femtech 3-year study showed exceptionally low complication rates, including 0.0% for capsular contracture, rupture, infection, seroma, hematoma, and changes in nipple/breast sensation, with a 1.0% reoperation rate.
• Post-market surveillance data for over 4.8 million Motiva Implants (October 2010 December 2025) indicates rupture and capsular contracture rates of less than 0.1%, with no reported cases of BIA-ALCL or SCC, which compares favorably to industry-wide concerns.
• Major competitors like Allergan Aesthetics (AbbVie), Mentor Worldwide LLC (Johnson & Johnson), and Sientra Inc. (Tiger Aesthetics Medical) possess significantly greater market share and resources, posing a competitive challenge despite Motiva's superior safety profile.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any material legal proceeding required to be disclosed under Item 103 of Regulation S-K.
• The company faces an inherent risk of product liability exposure related to the sale of Motiva Implants and other products, which could lead to claims if products fail to perform as designed or cause adverse events.
• The medical device industry is characterized by patent litigation, and the company could become subject to costly litigation or other proceedings to protect or enforce its intellectual property rights.

Related Party Transactions

• Generated $1.2 million in revenue in 2025 from product sales to Herramientas Medicas, S.A., a distribution company owned by a family member of the former Chief Executive Officer.
• Accounts receivable owed to the company from Herramientas Medicas, S.A. amounted to approximately $0.4 million as of December 31, 2025.
• Paid Dr. Chacón Quíros (brother of the former CEO) approximately $0.1 million in 2025 for training services at his clinic.
• Entered into a consulting agreement with former CEO Juan Jos Chacón-Quíros, effective June 1, 2025, providing $750,000 per year and an annual equity award with a target value of $750,000 for advisory and advocacy services.
• Granted a stock option award for 36,027 options with a grant date fair value of $0.9 million to Nicholas Lewin, a member of the board of directors, as compensation for consulting services.

Stakeholder Impact

• **Shareholders**: Potential for dilution from future equity raises; share price volatility risk; positive impact from strong revenue growth and reduced net losses; risk of substantial losses due to market factors and competitive pressures.
• **Customers (Physicians/Patients)**: Benefit from improved product safety and aesthetic outcomes with Motiva Implants and Mia Femtech; access to new product offerings like Preserv; enhanced warranty programs provide peace of mind; potential negative impact from product recalls or safety concerns (BIA-ALCL, SCC).
• **Employees**: Expected growth in employee numbers, particularly in manufacturing and sales/marketing; competitive job market in Costa Rica and other locations may impact retention; changes in executive leadership may create uncertainty.
• **Suppliers**: Reliance on a single-source supplier (Avantor) for critical raw materials poses a supply chain risk; Avantor's non-renewal of the supply agreement could lead to complex negotiations or the need to identify alternative suppliers.
• **Creditors**: Secured additional debt (Tranche D Term Loan, Inventory Funding Agreement); increased minimum liquidity requirements under the Credit Agreement; total debt obligations of $246.4 million principal as of December 31, 2025.

Next Steps

• Full commercial launch of Preserv in the United States is expected in 2026.
• Continued monitoring of patients in the U.S. IDE clinical trial for up to ten years post-implantation.
• The Post Approval Study (PAS) is currently enrolling 2,400 patients over a decade to investigate general post-market usage and endpoints.
• Negotiations with Avantor regarding future supply terms for medical-grade silicone are planned, as the current agreement's automatic renewal is not intended.
• Overall operating expenses are expected to increase in 2026 due to continued investment in commercial and operational activities.
• The company intends to continue improving its operational, financial, and management controls and systems.
• Potential strategic acquisitions of innovative products, services, and procedures that complement the existing portfolio may be pursued.

Key Dates

Recommendation

The company demonstrates strong revenue growth and improved gross margins, driven by successful U.S. market entry and positive clinical data for its innovative products. However, it continues to incur significant net losses and faces substantial risks, including reliance on a single critical supplier whose contract is not being automatically renewed, intense competition, and macroeconomic uncertainties. The positive developments are balanced by these ongoing challenges, suggesting a 'hold' position until there is clearer evidence of sustained profitability and resolution of key supply chain risks.

Keywords

Breast Implants, Medical Technology, Aesthetic Surgery, Motiva Implants, Mia Femtech, Preserv, Silicone Implants, FDA Approval, Financial Results, SEC Filing, ESTA, Biocompatibility, Qid RFID, SmoothSilk, Ergonomix, Breast Reconstruction, Costa Rica Manufacturing, Corporate Governance, Risk Factors, Financial Performance